<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451204</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS051591</org_study_id>
    <secondary_id>R01NS051591</secondary_id>
    <secondary_id>RG3915</secondary_id>
    <nct_id>NCT00451204</nct_id>
  </id_info>
  <brief_title>A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)</brief_title>
  <acronym>Estriol-MS</acronym>
  <official_title>A Combination Trial of Copaxone Plus Estriol in RRMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota, MN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Aurora</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blinded, placebo controlled study of estriol pills versus placebo pills in
      relapsing remitting multiple sclerosis. The study treatment will be an added on to Copaxone
      injections in all subjects. The primary outcome measure is a reduction in relapses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple sclerosis (MS) relapses are known to be significantly decreased during pregnancy.
      This proposal will establish whether oral treatment with estriol, the major estrogen of
      pregnancy, induces a decrease in relapses in relapsing remitting multiple sclerosis (RRMS)
      subjects when used in combination with injectable Copaxone. Previously, in a pilot study, it
      has been demonstrated that treatment of RRMS subjects with oral estriol for six months
      resulted in a significant reduction in gadolinium enhancing lesions on serial brain MRIs
      (Annals of Neurology, 2002; 52:421-428) and caused a favorable shift in immune responses
      (Journal of Immunology, 2003; 171:6267-6274). This is an add-on study aiming to extend these
      previous findings by treating longer and focusing on clinical outcomes. The combination of
      Copaxone injection plus estriol pill (8 mg per day) will be compared to Copaxone injection
      plus placebo pill in a double blind trial. The duration of treatment will be two years and
      the primary outcome measure will be relapse rate. Other outcomes will include disability
      measures and brain MRI outcomes. Safety measures (blood tests and gynecologic evaluations)
      will also be followed and correlations will be made between serum estriol levels with
      efficacy and safety. The overall goal of this study will be the development of a new oral
      treatment, estriol, for RRMS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Relapse, Annualized Relapse Rate</measure>
    <time_frame>24 months</time_frame>
    <description>A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse Event, Annualized Relapse Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Relapse, Probability of First Relapse</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Event, Probability of First Relapse Event</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Confirmed Relapse, Annualized Relapse Rate</measure>
    <time_frame>12 months</time_frame>
    <description>A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection.</description>
  </other_outcome>
  <other_outcome>
    <measure>Relapse Event, Annualized Relapse Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Estriol plus Copaxone injections QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estriol Capsules (daily) plus Copaxone injections (daily). Progestin capsules given for 2 weeks every 3 months to avoid unopposed estrogens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Copaxone injections QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Capsules (daily) plus Copaxone injections (daily). A second placebo capsule given for 2 weeks every 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estriol</intervention_name>
    <description>Estriol 8 mg capsule, once per day, duration of treatment is 2 years</description>
    <arm_group_label>Estriol plus Copaxone injections QD</arm_group_label>
    <other_name>E3</other_name>
    <other_name>estrogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule, once a day, treatment duration is 2 years</description>
    <arm_group_label>Placebo plus Copaxone injections QD</arm_group_label>
    <other_name>&quot;sugar pill&quot;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copaxone</intervention_name>
    <description>Injection, once a day, all subjects</description>
    <arm_group_label>Estriol plus Copaxone injections QD</arm_group_label>
    <arm_group_label>Placebo plus Copaxone injections QD</arm_group_label>
    <other_name>glatiramer acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of relapsing remitting multiple sclerosis

          -  At least one relapse in the last two years

        Exclusion Criteria:

          -  Patients treated in the past with total lymphoid irradiation, monoclonal antibody, T
             cell vaccination, cladribine, bone marrow transplantation, azathioprine,
             cyclophosphamide, methotrexate, mitoxantrone, cyclosporin or Tysabri

          -  Clinically significant diseases other than multiple sclerosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rhonda Voskuhl, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Los Angeles (UCLA), Los Angeles, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Cross, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University, Saint Louis, MO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elliot Frohman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas, Southwestern, Dallas, TX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suhayl Dhib-Jalbut, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert Wood Johnson Medical School, UMDNJ, New Brunswick, NJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Racke, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Reder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Rose, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Institute for Biomedical Research, Salt Lake City, UT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Giesser, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles (UCLA), Los Angeles, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Ratchford, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins, Baltimore, MD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon Lynch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gareth Parry, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, MN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dean Wingerchuk, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Corboy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Aurora</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Corey Ford, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico, Albuquerque</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dina Jacobs, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lloyd Kasper, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth University, Lebanon, NH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-6965</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Medical School</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ-Robert Wood Johnson Medical Center</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8575</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Institute for Biomedical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, Odesa S, Wu TC, Voskuhl RR. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002 Oct;52(4):421-8.</citation>
    <PMID>12325070</PMID>
  </reference>
  <reference>
    <citation>Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol. 2003 Dec 1;171(11):6267-74.</citation>
    <PMID>14634144</PMID>
  </reference>
  <reference>
    <citation>Morales LB, Loo KK, Liu HB, Peterson C, Tiwari-Woodruff S, Voskuhl RR. Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci. 2006 Jun 21;26(25):6823-33.</citation>
    <PMID>16793889</PMID>
  </reference>
  <reference>
    <citation>Tiwari-Woodruff S, Morales LB, Lee R, Voskuhl RR. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14813-8. Epub 2007 Sep 4.</citation>
    <PMID>17785421</PMID>
  </reference>
  <reference>
    <citation>Sicotte NL, Giesser BS, Tandon V, Klutch R, Steiner B, Drain AE, Shattuck DW, Hull L, Wang HJ, Elashoff RM, Swerdloff RS, Voskuhl RR. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol. 2007 May;64(5):683-8.</citation>
    <PMID>17502467</PMID>
  </reference>
  <reference>
    <citation>Gold SM, Sasidhar MV, Morales LB, Du S, Sicotte NL, Tiwari-Woodruff SK, Voskuhl RR. Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Lab Invest. 2009 Oct;89(10):1076-83. doi: 10.1038/labinvest.2009.79. Epub 2009 Aug 10.</citation>
    <PMID>19668239</PMID>
  </reference>
  <reference>
    <citation>Ziehn MO, Avedisian AA, Dervin SM, O'Dell TJ, Voskuhl RR. Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. Lab Invest. 2012 Aug;92(8):1234-45. doi: 10.1038/labinvest.2012.76. Epub 2012 Apr 23.</citation>
    <PMID>22525427</PMID>
  </reference>
  <reference>
    <citation>Spence RD, Hamby ME, Umeda E, Itoh N, Du S, Wisdom AJ, Cao Y, Bondar G, Lam J, Ao Y, Sandoval F, Suriany S, Sofroniew MV, Voskuhl RR. Neuroprotection mediated through estrogen receptor-alpha in astrocytes. Proc Natl Acad Sci U S A. 2011 May 24;108(21):8867-72. doi: 10.1073/pnas.1103833108. Epub 2011 May 9.</citation>
    <PMID>21555578</PMID>
  </reference>
  <results_reference>
    <citation>Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29.</citation>
    <PMID>26621682</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2007</study_first_submitted>
  <study_first_submitted_qc>March 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2007</study_first_posted>
  <results_first_submitted>January 20, 2016</results_first_submitted>
  <results_first_submitted_qc>May 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2016</results_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Rhonda Voskuhl</investigator_full_name>
    <investigator_title>Professor, Department of Neurology; Director Multiple Sclerosis Program</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>estrogen</keyword>
  <keyword>estriol</keyword>
  <keyword>progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Glatiramer Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Investigators interested in further research using the data should contact Dr. Voskuhl with proposed plans and request.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Estriol Capsules Plus Copaxone Injections</title>
          <description>Estriol: Estriol 8 mg capsule, once per day, duration of treatment is 2 years</description>
        </group>
        <group group_id="P2">
          <title>Placebo Capsules Plus Copaxone Injections</title>
          <description>Placebo: Placebo capsule, once per day, treatment duration is 2 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60">60 completed the study but 3 stopped study drug(s) early</participants>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient refusal</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Relapsing remitting multiple sclerosis women aged 18 to 50 years.</population>
      <group_list>
        <group group_id="B1">
          <title>Estriol Capsules Plus Copaxone Injections</title>
          <description>Estriol: Estriol 8 mg capsule, once per day, duration of treatment is 2 years</description>
        </group>
        <group group_id="B2">
          <title>Placebo Capsules Plus Copaxone Injections</title>
          <description>Placebo: Placebo capsule, once a day, treatment duration is 2 years</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="158"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="7.6"/>
                    <measurement group_id="B2" value="37.1" spread="7.3"/>
                    <measurement group_id="B3" value="37.4" spread="7.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Relapse, Annualized Relapse Rate</title>
        <description>A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection.</description>
        <time_frame>24 months</time_frame>
        <population>Included all as intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Estriol Capsules Plus Copaxone Injections</title>
            <description>Estriol: Estriol 8 mg capsule, once per day, duration of treatment is 2 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules Plus Copaxone Injections</title>
            <description>Placebo: Placebo capsule, once a day, treatment duration is 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Relapse, Annualized Relapse Rate</title>
          <description>A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection.</description>
          <population>Included all as intention to treat</population>
          <units>relapses per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.17" upper_limit="0.37"/>
                    <measurement group_id="O2" value="0.37" lower_limit="0.25" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>negative binomial regression</method>
            <method_desc>adjusted for age, BL EDSS score, # of relapses in previous 12 mo, time since dx, previous glatiramer acetate tx, and previous interferon beta tx.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse Event, Annualized Relapse Rate</title>
        <description>Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner.</description>
        <time_frame>24 months</time_frame>
        <population>Included all as intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Estriol Capsules Plus Copaxone Injections</title>
            <description>Estriol: Estriol 8 mg capsule, once per day, duration of treatment is 2 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules Plus Copaxone Injections</title>
            <description>Placebo: Placebo capsule, once per day, treatment duration is 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Event, Annualized Relapse Rate</title>
          <description>Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner.</description>
          <population>Included all as intention to treat.</population>
          <units>relapses per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.22" upper_limit="0.46"/>
                    <measurement group_id="O2" value="0.46" lower_limit="0.32" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>negative binomial regression</method>
            <method_desc>adjusted for age, BL EDSS score, # of relapses in previous 12 months, time since dx, previous GA treatment, and previous interferon beta treatment.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmed Relapse, Probability of First Relapse</title>
        <time_frame>24 months</time_frame>
        <population>All included as intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Estriol Capsules Plus Copaxone Injections</title>
            <description>Estriol: Estriol 8 mg capsule, once per day, duration of treatment is 2 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules Plus Copaxone Injections</title>
            <description>Placebo: Placebo capsule, once per day, treatment duration is 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Relapse, Probability of First Relapse</title>
          <population>All included as intention to treat</population>
          <units>probability of relapse at 24 months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="23.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="42.9" lower_limit="32.1" upper_limit="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>negative binomial regression</method>
            <method_desc>adjusted for age, BL EDSS score, # of relapses in previous 12 months, time since dx, previous GA treatment, and previous interferon beta treatment.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse Event, Probability of First Relapse Event</title>
        <time_frame>24 months</time_frame>
        <population>Included all as intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Estriol Capsules Plus Copaxone Injections</title>
            <description>Estriol: Estriol 8 mg capsule, once per day, duration of treatment is 2 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules Plus Copaxone Injections</title>
            <description>Placebo: Placebo capsule, once per day, treatment duration is 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Event, Probability of First Relapse Event</title>
          <population>Included all as intention to treat</population>
          <units>probability of relapse event at 24 mo</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="30.0" upper_limit="53.0"/>
                    <measurement group_id="O2" value="46.9" lower_limit="35.9" upper_limit="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.179</p_value>
            <method>negative binomial regression</method>
            <method_desc>adjusted for age, BL EDSS score, # of relapses in previous 12 months, time since dx, previous GA treatment, and previous interferon beta treatment.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Confirmed Relapse, Annualized Relapse Rate</title>
        <description>A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Estriol Capsules Plus Copaxone Injections</title>
            <description>Estriol 8 mg capsule, once per day, duration of treatment is 2 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules Plus Copaxone Injections</title>
            <description>Placebo capsule, once a day, treatment duration is 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Relapse, Annualized Relapse Rate</title>
          <description>A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection.</description>
          <units>relapses per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.16" upper_limit="0.40"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.33" upper_limit="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>negative binomial regression</method>
            <method_desc>adjusted for age, BL EDSS score, # of relapses in previous 12 months, time since dx, previous GA treatment, and previous interferon beta treatment.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Relapse Event, Annualized Relapse Rate</title>
        <description>Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Estriol Capsules Plus Copaxone Injections</title>
            <description>Estriol 8 mg capsule, once per day, duration of treatment is 2 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules Plus Copaxone Injections</title>
            <description>Placebo capsule, once a day, treatment duration is 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Event, Annualized Relapse Rate</title>
          <description>Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner.</description>
          <units>relapses per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.22" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.61" lower_limit="0.44" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>negative binomial regression</method>
            <method_desc>adjusted for age, BL EDSS score, # of relapses in previous 12 months, time since dx, previous GA treatment, and previous interferon beta treatment.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After enrollment, during the 24-month treatment period</time_frame>
      <desc>An adverse event is any condition that occurs after enrollment, whether or not considered related to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Estriol Capsules Plus Copaxone Injections</title>
          <description>Estriol: Estriol 8 mg capsule, once per day, duration of treatment is 2 years</description>
        </group>
        <group group_id="E2">
          <title>Placebo Capsules Plus Copaxone Injections</title>
          <description>Placebo: Placebo capsule, once a day, treatment duration is 2 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure/ pace maker implantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine headache related eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Acute appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>car accident related body numbness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Accidentally took other's drug</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right Knee Replacemebt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>MS Relapse (hospitalization)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart palpitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision problem (blurry, double)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/ vomitting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>GA injection systemic reaction (SOB, hot flashes)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory Infection</sub_title>
                <counts group_id="E1" events="33" subjects_affected="22" subjects_at_risk="82"/>
                <counts group_id="E2" events="38" subjects_affected="26" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arm/ leg numbness, tingling</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression/ Anxiety</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="23" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menses/ spotting</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Menstrual flow amount increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Menstrual cramp</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Uterus, endometrial thickness &gt; 8mm (ultrasound)</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="82"/>
                <counts group_id="E2" events="36" subjects_affected="27" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Uterus, endometrial biopsies performed</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Uterus, fibroibds (ultrasound)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Fibrocystic disease on clinical exam</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>GA injection area abnormalities</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="82"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rhonda Voskuhl</name_or_title>
      <organization>University of California Los Angeles</organization>
      <phone>310-206-4636</phone>
      <email>rvoskuhl@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

